全球阵发性睡眠性血尿症(PNH) 治疗市场规模、份额、趋势和成长分析报告（2026-2034 年）

预计阵发性睡眠性血尿症(PNH) 治疗的市场规模将从 2025 年的 43.2 亿美元增长到 2034 年的 88.4 亿美元，2026 年至 2034 年的复合年增长率为 8.28%。

由于人们对罕见血液疾病的认识不断提高以及诊断能力的进步，阵发性睡眠性血尿症(PNH) 治疗的全球市场正稳步增长。筛检的普及和流式细胞技术的进步使得早期检测成为可能，促进了治疗的广泛应用。生物目标疗法的日益普及显着提高了患者的生存率和生活质量，鼓励已开发市场和新兴市场的医疗机构采用更先进的治疗方案。

关键成长要素包括对补体抑制剂疗法的大力研发投入以及新型单株抗体开发平臺的拓展。已开发国家对孤儿药的监管支持和优惠的报销政策进一步推动了市场扩张。此外，新兴市场患者支援计画的改善和医疗服务的可近性提高，也促进了诊断和治疗率的提升，从而增强了整体市场需求。

展望未来，能够延长给药间隔并提高安全性的新一代疗法有望惠及市场。正在进行的以口服和皮下製剂为重点的临床试验可望提升患者的用药便利性和依从性。製药公司与研究机构之间的策略合作可望加速创新，而亚太地区和拉丁美洲地区医疗基础设施的扩建将在预测期内创造新的成长机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：阵发性睡眠性血尿症(PNH) 治疗药物的全球市场：依药物类别划分

• 市场分析、洞察与预测
• 氨基喹啉
• 单株抗体
• 补体抑制剂
• 免疫系统调节剂
• 保护剂

第五章 全球阵发性睡眠性血尿症（PNH）治疗药物市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 静脉注射
• 皮下注射
• 肌肉内部

第六章 全球阵发性睡眠性血尿症(PNH) 治疗药物市场：依患者族群划分

• 市场分析、洞察与预测
• 按年龄组
• 性别
• 地理分布

第七章 阵发性睡眠性血尿症(PNH) 治疗药物的全球市场：按分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房
• 专科药房

第八章 全球阵发性睡眠性血尿症(PNH) 治疗药物市场：依治疗阶段划分

• 市场分析、洞察与预测
• 一线治疗
• 二线治疗
• 支持性护理
• 移植后护理

第九章 全球阵发性睡眠性血尿症(PNH) 治疗药物市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Apellis Pharmaceuticals
  • Alexion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • CinnaGen Co
  • Ra Pharmaceuticals Inc
  • Amgen Inc
  • Achillion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • Biocad

The Paroxysmal Nocturnal Hemoglobinuria Drug Market size is expected to reach USD 8.84 Billion in 2034 from USD 4.32 Billion (2025) growing at a CAGR of 8.28% during 2026-2034.

The global paroxysmal nocturnal hemoglobinuria (PNH) drug market is witnessing steady growth due to rising awareness of rare blood disorders and improved diagnostic capabilities. Increased screening and advancements in flow cytometry testing have enabled earlier detection, supporting treatment uptake. The growing availability of targeted biologic therapies has significantly improved patient survival rates and quality of life, encouraging healthcare providers to adopt advanced treatment options across developed and emerging markets.

Key growth drivers include strong research investments in complement inhibitor therapies and the expanding pipeline of novel monoclonal antibodies. Regulatory support for orphan drugs and favorable reimbursement policies in developed economies further stimulate market expansion. In addition, patient advocacy programs and improved healthcare access in emerging countries are contributing to increased diagnosis and treatment rates, strengthening overall market demand.

Looking ahead, the market is expected to benefit from next-generation therapies offering longer dosing intervals and improved safety profiles. Ongoing clinical trials focused on oral and subcutaneous formulations may enhance patient convenience and compliance. Strategic collaborations between pharmaceutical companies and research institutions are likely to accelerate innovation, while expanding healthcare infrastructure in Asia-Pacific and Latin America will create new growth opportunities over the forecast period.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Aminoquinolines
• Monoclonal Antibodies
• Complement Inhibitors
• Immune System Modulators
• Protective Agents

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

By Patient Demographics

• Age Group
• Gender
• Geographic Distribution

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

By Treatment Stage

• First-Line Therapy
• Second-Line Therapy
• Supportive Care
• Post-Transplant Care

COMPANIES PROFILED

• Apellis Pharmaceuticals, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc, CinnaGen Co, Ra Pharmaceuticals Inc, Amgen Inc, Achillion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, F HoffmannLa Roche Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, Biocad
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Aminoquinolines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Complement Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immune System Modulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Protective Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY PATIENT DEMOGRAPHICS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient Demographics
• 6.2. Age Group Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gender Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Geographic Distribution Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY TREATMENT STAGE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Treatment Stage
• 8.2. First-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Second-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Supportive Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Post-Transplant Care Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Drug Class
  • 9.2.2 By Route Of Administration
  • 9.2.3 By Patient Demographics
  • 9.2.4 By Distribution Channel
  • 9.2.5 By Treatment Stage
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Drug Class
  • 9.3.2 By Route Of Administration
  • 9.3.3 By Patient Demographics
  • 9.3.4 By Distribution Channel
  • 9.3.5 By Treatment Stage
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Drug Class
  • 9.4.2 By Route Of Administration
  • 9.4.3 By Patient Demographics
  • 9.4.4 By Distribution Channel
  • 9.4.5 By Treatment Stage
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Drug Class
  • 9.5.2 By Route Of Administration
  • 9.5.3 By Patient Demographics
  • 9.5.4 By Distribution Channel
  • 9.5.5 By Treatment Stage
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Drug Class
  • 9.6.2 By Route Of Administration
  • 9.6.3 By Patient Demographics
  • 9.6.4 By Distribution Channel
  • 9.6.5 By Treatment Stage
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Apellis Pharmaceuticals
  • 11.2.2 Alexion Pharmaceuticals Inc
  • 11.2.3 Akari Therapeutics Plc
  • 11.2.4 CinnaGen Co
  • 11.2.5 Ra Pharmaceuticals Inc
  • 11.2.6 Amgen Inc
  • 11.2.7 Achillion Pharmaceuticals Inc
  • 11.2.8 Alnylam Pharmaceuticals Inc
  • 11.2.9 F. Hoffmann-La Roche Ltd
  • 11.2.10 Novartis AG
  • 11.2.11 Regeneron Pharmaceuticals Inc
  • 11.2.12 Biocad